Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Overview of attention for article published in Clinical Cancer Research, December 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 13 X users

Citations

dimensions_citation: 44 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 18 X posts from 13 X users, with an upper bound of 322,688 followers.

RT @conascent: https://t.co/jIeMHaAJM2

Reply Repost Favourite

RT @conascent: https://t.co/jIeMHaAJM2

Reply Repost Favourite

https://t.co/jIeMHaAJM2

Reply Repost Favourite

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia https://t.co/I3QiBPnQKF #ScientiaVH

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 14 additional X posts.